GlassScriptPhysician profile
Patrick B Truong
NPI 1326237819
$8,730.08
in general payments reported to CMS, 2019-2025
36 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,034 · 2020: $197 · 2021: $746 · 2022: $770 · 2023: $1,617 · 2024: $1,929 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,957 · Education: $26.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,956.80 |
| Education | $26.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,668.79 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Madrigal Pharmaceuticals | $616.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $578.05 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $542.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $390.36 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.83 | 2019-2024 | Xifaxan |
| Ardelyx, INC. | $262.79 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $245.95 | 2019-2024 | Entyvio |
| Gilead Sciences, INC. | $228.79 | 2019-2024 | |
| Novo Nordisk INC | $213.48 | 2022-2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $195.21 | 2019-2025 | Rebyota, Clenpiq |
| Celgene Corporation | $180.52 | 2021-2024 | Zeposia |
| Allergan, INC. | $143.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $131.41 | 2023-2024 | Andexxa |
| Fresenius Kabi USA, LLC | $120.67 | 2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $119.02 | 2019-2025 | Ocaliva |
| Glaxosmithkline, LLC. | $114.38 | 2019-2021 | |
| Capsovision, INC. | $97.66 | 2025 | Capsocam Plus |
| Qol Medical, LLC | $86.64 | 2019-2024 | Sucraid |
| Celltrion USA INC. | $47.78 | 2024 | Zymfentra, Vegzelma |
| Ironwood Pharmaceuticals, INC | $43.13 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $39.52 | 2024-2025 | Vowst |
| Genzyme Corporation | $37.62 | 2025 | |
| Exact Sciences Corporation | $35.67 | 2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $32.24 | 2024 | |
| Shionogi INC | $31.88 | 2019 | |
| Sarepta Therapeutics, INC. | $23.17 | 2021 | |
| Redhill Biopharma INC. | $22.24 | 2021 | |
| Cook Medical LLC | $22.21 | 2019 | |
| Merck Sharp & Dohme LLC | $19.75 | 2023 | Dificid |
| Braintree Laboratories, INC. | $19.53 | 2025 | Sutab |
| Nestle Healthcare Nutrition INC. | $18.80 | 2023 | |
| Phadia US INC. | $18.75 | 2022 | |
| W. L. Gore & Associates, INC. | $18.66 | 2020 | |
| Vivus LLC | $18.58 | 2025 | Pancreaze |
| Fujifilm Healthcare Americas Corporation | $15.73 | 2024 | Utaswako Afp-L3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Truong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.